Compare RGTIW & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RGTIW | IOVA |
|---|---|---|
| Founded | 2013 | 2007 |
| Country | United States | United States |
| Employees | 164 | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 1.6B |
| IPO Year | N/A | 2008 |
| Metric | RGTIW | IOVA |
|---|---|---|
| Price | $5.58 | $3.67 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $9.11 |
| AVG Volume (30 Days) | 88.0K | ★ 15.9M |
| Earning Date | 03-11-2025 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.84 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $11,892,000.00 | N/A |
| Revenue This Year | N/A | $51.55 |
| Revenue Next Year | N/A | $37.55 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.13 | $1.64 |
| 52 Week High | $46.78 | $5.63 |
| Indicator | RGTIW | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 35.27 | 48.08 |
| Support Level | $5.07 | $2.02 |
| Resistance Level | $6.63 | $4.34 |
| Average True Range (ATR) | 0.69 | 0.32 |
| MACD | -0.09 | -0.12 |
| Stochastic Oscillator | 6.11 | 12.50 |
Rigetti Computing Inc builds quantum computers and the superconducting quantum processors that power them. The Company sells 9-qubit to 108-qubit quantum computing systems under the Novera and Cepheus trade names. Through the Rigetti Quantum Cloud Services (QCS) platform, the Company's machines can be integrated into any public, private or hybrid cloud. The Company also operates in Fremont, California; London, United Kingdom; Adelaide, Australia; British Columbia, Canada and Mumbai, India. The Company's revenue is derived from operations in the United States and the United Kingdom.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.